Otivio AS is a medical device company founded in 2010 and based in Oslo, Norway. In 2021, subsidiaries were established in Denmark and Germany. Otivio’s CE-certified product, FlowOx™, is a novel and non-invasive medical device for hospital and home use. Applications include the treatment of peripheral arterial disease (PAD) related problems such as pain, reduced walking distance and chronic ulcers. The therapeutic value of FlowOx has been proven in numerous clinical and observational studies. Early patient data suggests that FlowOx may also be able to alleviate Multiple Sclerosis (MS) symptoms. The use of FlowOx™ is comfortable and easy: the system generates an intermittent negative pressure (INP) that stimulates the blood circulation in the lower legs and feet, thus improving the blood flow and oxygen supply. The company is looking for partners for commercial development. Contact Otivio at info@otivio.com for more information.
Looking for a particular Otivio AS employee's phone or email?
The Otivio AS annual revenue was $6 million in 2026.
Iacob Mathiesen is the CSO of Otivio AS.
3 people are employed at Otivio AS.
Otivio AS is based in Oslo, Oslo.
The NAICS codes for Otivio AS are [33, 339].
The SIC codes for Otivio AS are [38, 384].